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GUSTO-IV Substudy
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ppsala, Sweden; Edmonton, Canada; Durham, North Carolina; and Rotterdam, the Netherlands
OBJECTIVES This study was designed to evaluate biomarkers for selection of patients with non–ST-
segment elevation acute coronary syndromes (ACS) that derive mortality benefit from
revascularization.
BACKGROUND Biomarkers are essential for identification of patients at increased risk, which may be reduced
by revascularization.
METHODS During the initial 30 days, 2,340 patients of 7,800 (30%) with non–ST-segment elevation
ACS in the GUSTO (Global Utilization of Strategies To open Occluded arteries)-IV trial
underwent coronary revascularization. The 1-year mortality was calculated in 30-day survivors
stratified by status of revascularization and levels of biomarkers. A propensity score for
receiving revascularization was constructed and included in a survival analysis that also
included the time point of revascularization as a time-dependent covariate.
RESULTS Elevation of troponin-T or N-terminal pro-B-type natriuretic peptide (NT-proBNP) was
associated with a high mortality. In patients with either or both of these markers elevated, a
lower mortality following revascularization was observed. In contrast, patients without
elevation of these markers had low 1-year mortality without any reduction in mortality
following revascularization. In fact, in patients with normal levels of both troponin-T and
NT-proBNP, a significant increase in 1-year mortality after revascularization was observed.
Elevation of C-reactive protein, interleukin-6, creatinine clearance, and ST-segment depres-
sion was also related to a higher mortality. However, independent of these markers, mortality
was lower after revascularization.
CONCLUSIONS Markers of troponin-T and NT-proBNP not only assist in risk stratification of patients with
non–ST-segment elevation ACS but also appear to identify patients who have a reduced
mortality associated with early coronary revascularization. (J Am Coll Cardiol 2006;48:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.05.0561146–54) © 2006 by the American College of Cardiology Foundation
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Snstable coronary artery disease, such as unstable angina or
on–ST-segment elevation myocardial infarction (MI), is a
eterogeneous condition with a variable risk of subsequent
ardiac events. Early risk stratification is essential and is
sually performed with clinical baseline characteristics, clin-
cal findings, electrocardiogram (ECG) (1), and biochemical
arkers of myocardial damage (2). During the past few
ears, it has been proven that markers of reduced renal
unction, such as creatinine clearance (3), cardiac perfor-
ance (for example, N-terminal pro-BNP [NT-proBNP])
4,5), inflammation (e.g., C-reactive protein [CRP]) (6,7),
nd interleukin (IL)-6 (8) also provide independent prog-
ostic information on mortality.
From the *Uppsala Clinical Research Center and †Department of Clinical
hemistry, Uppsala, Sweden; ‡University of Alberta, Edmonton, Canada; §Duke
RI, Durham, North Carolina; and Thoraxcenter, Erasmus Medical Center,
otterdam, the Netherlands.f
Manuscript received November 30, 2005; revised manuscript May 16, 2006,
ccepted May 23, 2006.In the overall population, recent studies have convinc-
ngly shown that a strategy using early revascularization
rocedures reduces the risk of death and recurrent MI (9).
evascularization is, however, resource consuming and po-
entially hazardous. Therefore, clinicians need tools to select
atients with the greatest potential benefit from revascular-
zation. It has been shown that patients with troponin
levation or ST-segment depression derive a particular
enefit from revascularization procedures (10). Further-
ore, one study suggested that IL-6 also provides predictive
nformation regarding benefit from this treatment strategy
8). N-terminal pro-BNP and creatinine clearance are the
iochemical markers with the strongest relation to mortality
5,11). However, no consistent results have been published
egarding their ability to predict a particular mortality
eduction following revascularization therapy (12,13).
The GUSTO (Global Utilization of Strategies To open
ccluded arteries)-IV trial included 7,800 patients with non–
T-segment elevation acute coronary syndromes (ACS) (14)
or evaluation of abciximab as primary medical treatment.
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September 19, 2006:1146–54 Biomarkers and Benefit From Revascularizationhirty-day survivors who underwent revascularization had a
ower 1-year mortality compared with medically treated pa-
ients after correction for patient characteristics in multivariable
nalyses, including a propensity score that adjusted for covari-
tes that were associated with the likelihood of early revascu-
arization (15).
The aim of the present study was to evaluate whether
iochemical markers of myocardial damage, reduced myo-
ardial performance, inflammation, and renal insufficiency
re useful for the identification of patient subsets with
owered mortality after revascularization therapies.
ETHODS
atient selection and randomized treatment. The
USTO-IV trial included 7,800 patients with non–ST-
egment elevation ACS from 458 centers in 24 countries
uring 1999 and 2000 (14). Patients over 21 years of age
ith 1 or more episodes of angina lasting 5 min within
4 h of admission and either a positive cardiac troponin test
r 0.5mm of ST-segment depression were eligible. The
tudy was conducted in a double-blind fashion, with pa-
ients randomly assigned to three groups: abciximab infu-
ion for 24 h, abciximab infusion for 48 h, or corresponding
lacebo infusion. All patients received aspirin for long-term
reatment as well as either unfractionated heparin infusion
r subcutaneous dalteparin. Coronary angiography was dis-
ouraged until 12 h after the completion of the study agent
nfusion but was thereafter at the discretion of the treating
hysician. Myocardial infarction was defined as either a new
-wave or creatinine kinase-MB fraction 3 times the
ormal upper limit as previously presented in detail (14). At
2 months, data on all-cause mortality were collected.
here was no benefit of the randomized abciximab treat-
ent in any subgroup based on clinical characteristics or
evels of biomarkers.
aboratory analyses. Venous blood samples were obtained
ia a direct venous puncture at randomization. After cen-
rifugation, serum was frozen at 20°C in aliquots and sent
or central laboratory analyses of creatinine kinase-MB
raction levels. One aliquot of the samples at baseline was
Abbreviations and Acronyms
ACS  acute coronary syndromes
CI  confidence interval
CRP  C-reactive protein
ECG  electrocardiogram
GUSTO-IV  Global Utilization of Strategies To open
Occluded arteries-IV trial
IL  interleukin
MI  myocardial infarction
NT-proBNP  N-terminal pro-B-type natriuretic
peptide
PCI  percutaneous coronary intervention
RR  relative risktored at 70°C and sent in batches of 500 to the Depart- lent of Clinical Chemistry, Uppsala, Sweden, for analyses.
ne batch was unfortunately lost during transportation.
he levels of troponin-T were determined in 7,115 patients
y a third-generation assay on an Elecsys (Roche Diagnos-
ics, Basel, Switzerland) with a detection limit of 0.01 g/l.
-reactive protein concentrations were measured in 7,108
atients with a chemiluminescent enzyme-labeled immuno-
etric assay (Immulite CRP, Diagnostic Products Corpo-
ation, Los Angeles, California) with a detection limit of 0.1
g/l. Measurements of plasma levels of IL-6 were per-
ormed in 6,857 patients with a commercial enzyme-linked
mmunosorbent assay (Quantikine, R&D systems, Abing-
on, United Kingdom) with a detection limit of 0.7 ng/l.
erum NT-proBNP was determined in 6,809 patients with
sandwich immunoassay on an Elecsys 2010 (Roche
iagnostics, Basel, Switzerland). Serum creatinine for 7,703
atients was analyzed at local laboratories. The creatinine
learance rate was calculated with the Cockcroft and Gault
quation: [(140  age)  (weight, kg)]/serum creatinine
mol/l) (16). Baseline ECG was performed in all 7,800
atients.
tatistical analyses. Patients who underwent revascular-
zation within 30 days after enrollment were compared with
hose who did not undergo such a procedure. Because
atients who underwent revascularization within 30 days
ere selected and survived at least until their revasculariza-
ion, which may introduce bias, all univariable analyses
egarding potential beneficial effect of revascularization were
estricted to 30-day survivors.
However, because the treatment itself causes an early
ncreased risk of death, exclusion of deceased patients may
lso overestimate the treatment effect. Both these biases
ere avoided by redefining the risk sets for every time point,
llowing patients to move from the non-revascularized to
he revascularized group at the time of revascularization. To
djust for baseline differences between the revascularized
nd non-revascularized patients, a propensity score (17)
stimating the probability of revascularization was calcu-
ated through a logistic regression model. A selection was
one among a large number of the baseline variables, and the
nal model included the following variables: age, gender,
egion (Western Europe, Eastern Europe, North America, and
thers), race, diabetes status, history of heart failure, treatment
ith beta-blockers, nitroglycerin, digitalis, ST-segment de-
ression at admission, and time from symptom onset to
andomization. Age was entered as a quadratic polynomial.
wo interactions with region were also included: treatment
ith nitroglycerin and history of percutaneous coronary inter-
ention.
The revascularization rate was markedly lower in Eastern
urope (11.5%) as compared with the rest of the world
38%), and the procedure-related mortality (within 30 days
fter revascularization) was substantially higher, 6% versus
% after percutaneous coronary intervention (PCI) and 18%
ersus 7% after coronary artery bypass grafting (Fig. 1). The
ikelihood of revascularization by multivariable analyses was
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Biomarkers and Benefit From Revascularization September 19, 2006:1146–54ositively associated with admission outside of Eastern
urope, increasing age, male gender, prior nitroglycerin and
eta-blocker therapy, ST-segment depression, absence of
iabetes, previous heart failure, and digitalis treatment.
ence, the calculated propensity score for revascularization
as strongly dominated by region, making it difficult to
nclude the propensity score for the entire population in the
nal multivariable analysis. Therefore, patients from East-
rn Europe were excluded and the propensity score refitted
n the final analyses.
The average risk of death was then calculated as the
umber of cases per aggregated person-time at risk for each
roup (revascularized/non-revascularized). To be able to
igure 1. Mortality in subgroups of patients stratified by type of
nterventional treatment: percutaneous coronary intervention (PCI) and
oronary artery bypass grafting (CABG). (A) Outside of Eastern
urope; (B) Eastern Europe.djust for the propensity score and other variables, a tarametric survival model assuming an exponentially dis-
ributed survival time was formulated.
Finally, the relative reduction in mortality following
evascularization was estimated for subgroups defined by
ifferent levels of biochemical markers. Differences between
he markers regarding their ability to select subsets of
atients with lower mortality following revascularization
ere tested by inclusion of a multiplicative interaction term
n the model. The following cutoff values were used:
roponin-T (0.01 g/l  lowest detection limit and 25th
ercentile), NT-proBNP (237 ng/l 25th percentile), IL-6
10 ng/l  75th percentile), CRP (10 mg/l  75th
ercentile), and creatinine clearance (50.7 ml/min  25th
ercentile) based on experience from previous publications
5,18). All calculations were done using the statistical
rogram R (19).
ESULTS
evascularization. The patient population is well charac-
erized and has been described in detail previously (14).
aseline characteristics for patient strata based on levels of
roponin-T and Nt-proBNP are shown in Table 1. In
ccordance with the protocol, only 147 patients (2%) were
evascularized during the 48 h of study drug infusion.
owever, within 30 days after inclusion, coronary an-
iography was performed in 3,804 patients (49%), and a
otal of 2,340 (30%) patients had undergone revascular-
zation on clinical indications. Coronary bypass surgery
as performed in 831 patients after a median of 12 days,
nd 1,481 patients underwent PCI after a median of 7
ays. Both coronary artery bypass grafting and PCI were
erformed in 26 patients. Differences between patients
eceiving and not receiving revascularization have been
escribed previously (15).
bserved reduction of mortality following revasculariza-
ion. Among 30-day survivors, patients who underwent
evascularization during the initial 30 days after admission
ad a significantly lower mortality compared with those who
id not undergo revascularization, as presented in a previous
ublication from our group (15). In patients with elevation
f troponin-T 0.01 g/l, a significantly lower 1-year
ortality in patients who underwent revascularization dur-
ng the initial 30 days, as compared with those who did not
ndergo revascularization, was observed; 6.9% versus 2.2%,
 0.001 (Table 2, Fig. 2A). Among the troponin-negative
atients, there was no statistically significant difference in
he crude mortality among those who received or did not
eceive revascularization (2.6% vs. 3.0%, p 0.7). Similarly,
lower mortality following revascularization was also ob-
erved in patients with elevation of NT-proBNP (237
g/l, 7.0% vs. 2.7%, p  0.001). In patients with NT-
roBNP 237 ng/l, there was no difference in 1-year
ortality between revascularized and non-revascularized
atients (1.2% vs. 1.2%, p  1.0) (Fig. 2B). Revasculariza-
ion was associated with a significantly lower 1-year mor-
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September 19, 2006:1146–54 Biomarkers and Benefit From Revascularizationality independent of levels of creatinine clearance, although
he absolute difference was greater in the high-risk patients
ith a creatinine clearance below 51 ml/min. Similarly,
hen stratifying the patients for levels of the inflammatory
arkers, the mortality was significantly lower following
evascularization independent of levels of IL-6 (Fig. 2D) or
RP (data not shown), although the absolute reduction of
ortality was larger in patients with higher compared with
ower levels of the inflammation markers. Also, when the
atients were stratified for the occurrence of ST-segment
epression (0.5 mm) at admission, the relative observed
mprovement in outcome following revascularization was
imilar among patients with and without ST-segment
epression. The absolute improvement, as expected, was
arger in patients with ST-segment depression (data not
hown). As both troponin-T and NT-proBNP appeared to
tratify patients with versus without improvement in out-
ome following revascularization, the combination of the
Table 1. Baseline Characteristics for Patient-S
NT-proBNP
TnT, g/l
<0.01 >0
Age (yrs), mean  SD 64  11 66 
Weight (kg), mean  SD 76  13 78 
Male gender, % 48.3 67
Current smoking, % 16.6 24
History of stroke, % 1.5 2
Heart failure, % 7.7 7
Hypercholesterolemia, %* 35.0 29
Angina pectoris, % 60.6 42
Hypertension, % 57.4 49
Diabetes mellitus, % 18.4 22
Previous MI, % 28.2 32
Previous revascularization, % 16.4 15
ST-segment depression 93.2 76
*History of hypercholesterolemia requiring medical therapy.
MI  myocardial infarction; NT-proBNP  N-termina
Table 2. One-Year Mortality in Relation to Pe
and Levels of Biomarkers
Marker
Univar
Patients
Mortality
No Revasc
TnT 0.01 g/l 1,779 2.6 (42)
TnT 0.01 g/l 5,336 6.9 (222)
NT-proBNP 237 ng/l 1,702 1.2 (15)
NT-proBNP 237 ng/l 5,107 7.0 (235)
Il-6 10 ng/l 5,143 4.5 (158)
Il-6 10 ng/l 1,714 8.4 (95)
CRP 10 mg/l 5,331 4.2 (155)
CRP 10 mg/l 1,777 9.3 (107)
Creacl 51 ml/min 5,777 3.5 (134)
Creacl 51 ml/min 1,926 11.6 (157)
*Patients not surviving 30 days excluded. †Adjusted for a p
mortality. The time point of revascularization was entered a
excluded. ‡The p values indicate the test for difference bet
mortality following revascularization.CI  confidence interval; Creacl  creatine clearance; CRP 
other abbreviations as in Table 1.arkers were evaluated in patients surviving 30 days
Fig. 3). Among the 950 patients without elevation of either
f the markers, 154 patients underwent revascularization
nd had a higher crude mortality than patients that did not
ndergo revascularization (3.2% vs. 0.6%, p  0.04). For
atients with either of the markers positive, 1-year mortality
as lower with revascularization (1.3% vs. 3.7%, p 0.001).
inally, among the 3,914 patients with both markers posi-
ive, a clearly lower 1-year mortality after revascularization
as observed (2.6% vs. 7.6%, p  0.001).
ultivariable survival analyses. Among patients with
roponin-T elevation (0.01 g/l), there was a significantly
ower mortality associated with revascularization (relative
isk [RR] 0.56, 95% confidence interval [CI] 0.4 to 0.7)
Table 1, Fig. 4). On the contrary, among troponin-
egative patients, revascularization tended to be associated
ith an increase in mortality (RR 1.79, 95% CI 0.96 to 3.8).
he difference in risk ratio between troponin-positive
Based on Levels of Troponin-T and
p
NT-proBNP, ng/l
p<237 >237
0.001 59  10 67  11 0.001
0.001 80  13 76  13 0.001
0.001 65.9 60.5 0.001
0.001 28.6 20.7 0.001
0.02 1.0 2.7 0.001
0.6 2.8 9.0 0.001
0.001 31.9 30.7 0.3
0.001 42.0 48.8 0.001
0.001 44.5 54.2 0.001
0.01 13.7 23.3 0.001
0.02 17.9 34.8 0.001
0.13 11.3 16.5 0.001
0.001 84.8 79.6 0.001
-type natriuretic peptide; TnT  troponin-T.
ed Revascularization in the Initial 30 Days
Multivariable
Survival Model†n)
p Valuevasc RR 95% CI p Value‡
(11) 0.7 1.79 (0.96, 3.8) 0.004
(37) 0.001 0.56 (0.4, 0.7)
(5) 1.0 1.91 (0.7, 5.3) 0.04
(40) 0.001 0.63 (0.5, 0.8)
(30) 0.001 0.77 (0.6, 1.1) 0.39
(17) 0.001 0.61 (0.4, 0.9)
(24) 0.001 0.54 (0.4, 0.8) 0.03
(25) 0.01 0.94 (0.7, 1.4)
(35) 0.01 0.76 (0.5, 1.0) 0.30
(18) 0.001 0.60 (0.4, 1.8)
sity score for revascularization and predictors for increased
e-dependent covariate. Patients from Eastern Europe were
the marker groups with regard to the relative reduction intrata
.01
11
14
.5
.8
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.2rform
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Biomarkers and Benefit From Revascularization September 19, 2006:1146–54nd -negative patients was highly significant (p  0.003).
imilarly, 1-year mortality was significantly lower with
evascularization in patients with NT-proBNP above the
5th percentile of 237 ng/l (RR 0.63, 95% CI 0.5 to 0.8).
mong patients with Nt-proBNP below 237 ng/l, on the
ther hand, revascularization tended to be associated with
n increase in mortality (RR 1.91, 95% CI 0.7 to 5.3). Thus,
here was also a significant interaction between the NT-
ro-BNP level and revascularization on 1-year mortality
p  0.04). For patients with a creatinine clearance below
he 25th percentile of 51 ml/min who were at high risk,
evascularization was associated with a significantly lower
ortality. However, patients with creatinine clearance
bove the cutoff also tended to have a similar lower mortality
ollowing an invasive treatment. Thus, the risk ratios did not
iffer between the two groups, and the interaction was not
ignificant (p  0.3). Although elevation of IL-6 was
elated to increased 1-year mortality, the relative reduction
igure 2. Cumulative mortality estimated by the Kaplan-Meier method o
evels of biochemical markers. (A) Troponin-T (TnT) above or below the d
eptide (Nt-proBNP) above or below the median of 237 ng/l at admission
l/min at admission; (D) interleukin-6 (Il-6) above or below the third quf mortality following invasive therapy was similar in tatients with levels above or below the 75th percentile of 10
g/l. The CRP elevation was associated with a higher
ortality, but only patients with CRP levels below the 75th
ercentile of 10 mg/l had a significant relative reduction of
ortality following revascularization in the multivariable
odel. All results were generally unaltered, with the cut
oints at the medians of the markers (troponin-T 0.11 g/l,
RP 4.0 mg/l, IL-6 5 ng/l, NT-proBNP 669 ng/l, and
reatinine clearance 66 ml/min).
In patients with elevation of both troponin-T and NT-
roBNP, a significantly lower mortality after revasculariza-
ion was observed, with a relative risk of 0.55 (95% CI 0.4,
.7) (Fig. 5). On the contrary, revascularization was associ-
ted with a significant hazard, with a relative risk of 10.8
95% CI 2.1 to 56) in patients without elevation of either
roponin-T or NT-proBNP. With a cutoff for NT-proBNP
t the median of 669 ng/l, the result pointed in the same
irection with a narrower CI (relative risk 4.6, 95% CI 1.6
day survivors stratified by revascularization (revasc.) status at 30 days and
ion limit of 0.01 g/l at admission; (B) N-terminal pro-B-type natriuretic
creatinine clearance (Crea. cl) above or below the first quartile limit of 51
limit of 10 ng/l at admission.f 30-
etecto 13.7).
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September 19, 2006:1146–54 Biomarkers and Benefit From RevascularizationISCUSSION
oderate- to high-risk patients with non–ST-segment
levation ACS are recommended to be treated with early
evascularization, as this strategy has proven to reduce
ymptoms of angina, reduce the number of readmissions,
horten the length of hospital stay, and lower the risk of
igure 3. One-year mortality for 30-day survivors stratified by revasculariz
T-proBNP (237 ng/l and 237 ng/l). Black bars represent patients
evascularization the initial 30 days. Abbreviations as in Figure 2.
igure 4. Risk ratios regarding 1-year mortality following revascularizat
ncluding a propensity score of receiving revascularization and other confou
ifference between the relative risks for positive versus negative markers. A relati
ith revascularization. Patients from Eastern Europe were excluded. CRP  Coronary events (9,20,21). Only one randomized trial has
hown a reduction of mortality (9), whereas there was an
ncreased mortality with early angiography and revascular-
zation as the standard treatment strategy in one of the early
tudies (22). An important remaining question is, therefore,
ow to select patients who may particularly derive a mor-
status and combinations of troponin-T (0.01 g/l and 0.01ug/l) and
nderwent revascularization and gray bars, patients who did not undergo
f patients stratified by biomarker status in a parametric survival model,
variables of increased mortality. The p values indicate the significance ofationion o
ndingve risk ratio and 95% confidence intervals 1.0 indicate a lower mortality
-reactive protein; other abbreviations as in Figure 2.
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Biomarkers and Benefit From Revascularization September 19, 2006:1146–54ality benefit from early revascularization. In the present
tudy we have shown that biomarkers of myocardial damage
nd dysfunction are not only useful for prediction of high
ortality in patients with non–ST-segment elevation ACS
ut also for the prediction of a reduced mortality following
evascularization. Furthermore, and equally important, nor-
al levels of these markers appear to identify subgroups of
atients with a low mortality, which is, in fact, increased by
n invasive therapy.
roponin. In accordance with previous randomized studies
egarding the invasive treatment, troponin was shown to be the
iomarker with the best ability to predict improvement in
utcome following revascularization (10,23). In the
USTO-IV trial, revascularization was not randomized,
hich makes is possible that troponin levels biased the selec-
ion of patients for angiography and revascularization. How-
ver, after correction for the propensity score for revasculariza-
ion and with the time point of revascularization entered as a
ime-dependent covariate, all of the observed improvement in
urvival following coronary revascularization was found among
he troponin-positive patients, with a tendency to an increased
ortality for the troponin-negative patients. The results of the
ACTICS–TIMI-18 (Treat Angina with Aggrastat and de-
ermine Cost of Therapy with an Invasive or Conservative
trategy) trial pointed in the same direction, with a significant
igure 5. Risk ratios regarding 1-year mortality following revascularization
urvival model adjusted for a propensity score of receiving revascularization
f revascularization as a time-dependent variable. The p values indicate
ortality following revascularization. A relative risk ratio and 95% confiden
s in Figure 2.eduction of the combined end point of death or MI at 6 donths only for the troponin-positive patients (10). Similarly,
n the FRISC (Fragmin and fast Revascularization during
nStability in Coronary artery disease)-II trial, mortality at 12
onths was reduced significantly among the troponin-positive
atients (24). The relation between levels of troponin-T and
xtent of coronary disease and the likelihood of embolization of
oronary thrombi may explain the reduction of mortality with
evascularization in troponin-positive patients (25). On the
ther hand, the tendency toward an increased mortality with
evascularization in troponin-negative patients may be ex-
lained by the lower mortality overall in this subgroup.
-type natriuretic peptide. B-type natriuretic peptide and
he N-terminal part of its prohormone, NT-proBNP, are
mong the most powerful biomarkers for prediction of
ortality in patients with non–ST-segment elevation ACS
5). Yet, no previous study has clearly shown that levels of
T-proBNP may be useful for the prediction of benefit or
arm of revascularization. In the GUSTO-IV, revascular-
zation was associated with an absolute risk reduction of
.3% in 30-day survivors with a positive NT-proBNP. A
imilar tendency was found in the TACTICS–TIMI-18
rial, in which patients with a BNP level above 80 ng/l
ended to have a lower mortality after an invasive strategy
7.9% vs. 9.0%). On the contrary, in patients with a BNP
evel below 80 ng/l, the invasive strategy did not tend to
ients stratified by combinations of biomarkers in a multivariable parametric
other significant variables of increased mortality as well as the time-point
st for difference between the marker groups regarding the reduction of
rvals1.0 indicate a lower mortality with revascularization. Abbreviationsof pat
and
the teecrease the overall low mortality (1.9% vs. 1.6%) (13).
S
t
r
p
n
t
(
t
t
(
p
l
a
i
v
l
i
B
s
a
d
o
t
I
l
p
t
o
s
n
F
d
e
a
n
p
b
s
m
e
C
t
e
l
c
1
t
e
t
a
S
o
s
o
c
i
s
b
W
a
s
i
c
m
e
d
E
C
t
c
c
l
b
r
w
m
p
M
b
s
R
m
E
R
1153JACC Vol. 48, No. 6, 2006 James et al.
September 19, 2006:1146–54 Biomarkers and Benefit From Revascularizationimilarly, in the FRISC II trial an invasive strategy tended
o reduce mortality from 10.8% to 7.2% (absolute risk
eduction 3.6%, p  0.11) among patients with NT-
roBNP levels in the top tertile (906 ng/l for men and 1,345
g/l for women). There was, however, no mortality reduc-
ion in patients with NT-proBNP in the bottom tertiles
2.6% to 2.0%) (12). In the present study, the 25th percen-
ile of 237 ng/l was chosen as the cut point, which is close
o the 97.5th percentile of 290 ng/l in healthy individuals
26). The results pointed in the same direction as other cut
oints of the markers.
Patients without elevation of NT-proBNP have a low
ikelihood of other concomitant cardiovascular disorders
nd are at a very low long-term risk of death (5). The
ncreased short-term risk associated with a coronary inter-
ention in general, and coronary bypass surgery in particu-
ar, may not be offset by any long-term mortality reduction
n these low-risk patients. Patients with elevated levels of
NP (or NT-proBNP), on the other hand, have been
hown to have more concomitant cardiovascular diseases
nd a greater extent and severity of the ischemic territory
uring the index event. These factors may explain the
bserved lower mortality in association with revasculariza-
ion (27).
nflammatory markers. Although there was an observed
ower mortality with revascularization in IL-6 positive
atients after multivariable correction in the present study
here was no differential benefit of revascularization based
n either of the inflammatory markers in contrast to the
ubstudy results of the FRISC II trial (8). The results did
ot change if a cut point for IL-6 similar to the one in the
RISC substudy (6 ng/l) was chosen. The reason for the
ivergent results in the two studies is unclear but may be
xplained by different methods and sensitivity of the IL-6
nalyses. ST-segment depression on admission ECG did
ot predict any particular reduction in mortality in the
resent study in contrast to previous studies (23). This may
e explained by the low level for the definition of ST-
egment depression (0.05 mV) in the GUSTO-IV trial,
aking the variable rather unspecific for prognostic
valuation.
ombination of markers. Patients without elevation of
roponin-T or NT-proBNP in the present study had an
xtremely low 1-year mortality of 1.6%. Thus, there is a very
ow potential for improvement in outcome following revas-
ularization (5). Despite the low overall risk in this cohort,
54 of 950 patients (16%) in fact underwent revasculariza-
ion on clinical grounds during the 30 days after the index
vent. Our observational data suggest that it may be harmful
o revascularize this group of low-risk patients despite an
ngiographically proven coronary disease.
tudy limitations. The present study is post-hoc analysis
f non-randomized data. Because of the extensive analysis,
tatistical power may be limited. However, the large number
f included patients with a high event rate and the extensive
ollection of biomarkers should lend support to our mortal-ty subset analyses. Furthermore, through our propensity
core analyses, we have attempted to control for selection
ias in the decision to perform coronary revascularization.
e also used revascularization as a time-dependent variable
mong other predictors of increased mortality in the final
urvival model. Because the propensity score for revascular-
zation was completely dominated by region, patients in-
luded in Eastern Europe were excluded in the final
ultivariable model for statistical reasons. There was, how-
ver, no indication that the evaluated biomarkers had
ifferent relations to crude mortality for patients in Eastern
urope or in other regions.
onclusions. Our data show that measurement of
roponin-T and NT-proBNP levels improves risk stratifi-
ation of patients with non–ST-segment elevation ACS. In
enters where early revascularization can be performed with
ow procedural mortality, patients with elevated levels of
oth markers are at high risk of death that appears to be
educed by coronary revascularization. In addition, patients
ith low levels of both these markers have a very low 1-year
ortality with medical management, and early invasive
rocedures appear to increase their overall risk of mortality.
easurement of troponin-T and NT-proBNP levels should
e included in risk stratification and early management
trategy decisions for patients with ACS.
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